Despite winning US Food and Drug Administration approval for a new antibiotic last year, Achaogen has filed for bankruptcy. The South San Francisco–based biotech firm launched the antibiotic, Zemdri (plazomicin), in July for adults with complicated urinary tract infections. However, by the end of the year the drug had brought in only $800,000 in sales. Achaogen hopes to sell off its assets, including Zemdri, by June 13.There's a little factlet for those of us who bemoan the state of the antibiotics pipeline.
Wednesday, April 24, 2019
Sad news for Achaeogen
Also in this week's issue of C&EN (by Michael McCoy):